Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
11.69
-0.13 (-1.10%)
Nov 20, 2025, 4:00 PM EST - Market closed
CRBP Employees
Corbus Pharmaceuticals Holdings had 28 employees as of December 31, 2024. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$2,411,143
Market Cap
205.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | 9 | 47.37% |
| Dec 31, 2023 | 19 | -14 | -42.42% |
| Dec 31, 2022 | 33 | -8 | -19.51% |
| Dec 31, 2021 | 41 | -35 | -46.05% |
| Dec 31, 2020 | 76 | -65 | -46.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRBP News
- 14 days ago - Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis - Seeking Alpha
- 21 days ago - Corbus Pharmaceuticals Announces Pricing of Public Offering - GlobeNewsWire
- 21 days ago - Corbus Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 4 weeks ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript - Seeking Alpha
- 4 weeks ago - Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 - GlobeNewsWire
- 2 months ago - FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
- 5 months ago - Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab - GlobeNewsWire